
Overview
Medicofarma is a company specializing in contract manufacturing of pharmaceuticals and dietary supplements. It is the first Polish producer of a COVID-19 test, known as MediPAN-2G+ FAST COVID, which is recognized for its speed and sensitivity. The company also operates a Research and Development Laboratory to innovate in health protection and produce various pharmaceutical forms.
Financials
Revenue history (in m)
Filing timeliness
No financial statement for 2025 – the filing deadline has passed. 6 of 6 financial statements were filed late (the longest delay 181 days for 2019). All were audited by a statutory auditor.
- 2025not filed
- 202429/10/2025
- 202301/08/2024
- 202221/08/2023
- 202113/12/2022
- 202003/11/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2024.
Results vs industry
News

Medicofarma produces the Polish MediPAN-2G+ FAST COVID test. Poland can become independent of imported tests

Medicofarma launches the MediPAN-2G+ FAST COVID coronavirus test in Poland

Medicofarma to launch a Polish coronavirus test using Real-time RT-PCR

Medicofarma produced a pilot batch of the first Polish coronavirus tests

Medicofarma to produce coronavirus detection tests for Hemp&Health, a NewConnect company

First test differentiating COVID-19 and influenza
Industry
Public procurement
2 tenders recorded as contractor: 1 national ($33,109) and 1 EU ($215,735).
| Publication date | Subject | Amount | Contracting authority | |
|---|---|---|---|---|
| Aug 26, 2024 | Repackaging and blinding of medicines containing the active substances pirfenidone and nintedanib | $215.7K$215,735 | Narodowy Instytut Geriatrii,Reumatologii I Rehabilitacji Im. Prof. Dr Hab. Med. Eleonory Reicher | |
| May 2, 2022 | Supply of placebo and reference medicinal product in connection with the conduct of a non-commercial clinical trial | $33,109$33,109 | Wojskowy Instytut Medyczny - Państwowy Instytut Badawczy |
Trademarks
The company holds 26 active trademarks registered with the Polish Patent Office. 22 marks have expired or were not registered. The first mark was filed in 2003.
| Mark | Protected until | |
|---|---|---|
| ENCOPIRIN (word) | Jun 28, 2033 | |
| MediPAN-2G+ (word) | Aug 10, 2030 | |
| FEVERINEX (word) | May 25, 2030 | |
| VIRUNAZON (word) | May 25, 2030 | |
| ADAROSTIN (word) | May 19, 2030 |
Authorized Representatives
Manner of representation
Each member of the management board acting independently.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2001-01-10.
Debt
No entries in the National Debtors Register (KRZ).
MSiG notices
7 notices recorded in the Court and Commercial Gazette (MSiG).
| Publication date | Event | |
|---|---|---|
| Feb 29, 2016 | Commercial Companies Code notice | |
| Jun 22, 2015 | Shareholders' meeting convened | |
| Jul 31, 2014 | Commercial Companies Code notice | |
| Aug 6, 2013 | Shareholders' meeting convened | |
| Feb 8, 2013 | Shareholders' meeting convened |
Public aid
22 public aid cases recorded, with a total value of $3,337,909.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Mar 31, 2026 | Regional investment aid | $293.1K$293,105 | DRUGI MAZOWIECKI URZĄD SKARBOWY W WARSZAWIE | |
| Jan 30, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $1,092$1,092 | Prezes Banku Gospodarstwa Krajowego | |
| Jan 9, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $68$68 | PGE Obrót S.A. |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2019-07-01 | Implementation of R&D results and launch of production of innovative dermocosmetics containing the patented 4-N-furfurylcytosine molecule. | $1.3M$1,292,712 | Operational Programme Smart Growth |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Exim Pharma sp. z o.o. | $24,694,130.27 | eximpharma.eu | ||
| Przedsiębiorstwo Produkcyjno-Handlowe Ewa S.A. | $14,322,437.53 | ewa-sa.pl | ||
| Valentis Polska sp. z o.o. | $13,271,939.35 | valentis.pl | ||
| Biofaktor sp. z o.o. | $10,761,755.73 | biofaktor.pl | ||
| Ośrodek Badawczo-Produkcyjny Politechniki Łódzkiej Ichem sp. z o.o. | $10,474,927.81 | ichem.com.pl | ||
| Wellmedica Hf sp. z o.o. | $8,037,044.71 | wellmedica.pl | ||
| Nutramatic sp. z o.o. | $6,205,312.16 | nutramatic.pl | ||
| Tantus sp. z o.o. | $5,274,248.80 | tantus.pl | ||
| Bioactive T sp. z o.o. | $1,599,993.10 | bioactivet.pl | ||
| Grand Medical Poland sp. z o.o. | $1,394,971.29 | grandmedical.pl |
Change history
| Date | Event | |
|---|---|---|
| 2019-11-27 | Share capital increase (20,000,000.00 PLN → 21,000,000.00 PLN) | |
| 2019-08-21 | Share capital increase (17,000,000.00 PLN → 20,000,000.00 PLN) | |
| 2015-12-07 | Address change (Sokołowska 9/19, 01-142, Warszawa → Ul. Sokołowska 9/U19, 01-142, Warszawa) | |
| 2015-12-07 | PKD change (Removed: 12 codes; Added: 3 codes) | |
| 2013-04-12 | Share capital increase (16,000,000.00 PLN → 17,000,000.00 PLN) |
FAQ
Last updated: 2026-03-22
